BMJ  2004;329:1169-1172 (13 November), doi:10.1136/bmj.329.7475.1169

Education and debate

The concept of essential medicines: lessons for rich countries

¹ Drugs and Medicines Policy, World Health Organization, Geneva, Switzerland hogerzeilh@who.int

Rich countries should follow the lead of poor countries and adopt a more systematic way of controlling the cost of drugs

The first 150 words of the full text of this article appear below.

Introduction

Industrialised countries, faced with increasing demands for quality health care by ageing populations and ever increasing costs of medicines, can learn from low income countries how to respond to pharmaceutical policy issues in a comprehensive way.

Since the 1970s many developing countries have started national programmes for essential drugs to promote the availability, accessibility, affordability, quality, and rational use of medicines. The cornerstones of such programmes are the careful selection of essential medicines for public supply and reimbursement, based on a systematic review of comparative efficacy, safety, and value for money; evidence based national clinical guidelines as the basis for training and rational prescribing; and a national medicines policy to balance conflicting policy objectives and to express government commitment to a common goal. Industrialised countries would do well to consider and adopt these approaches, which have been so beneficial to developing countries.

The concept of essential medicines

The concept of essential medicines was launched in . . . [Full text of this article]

-->

The link with national clinical guidelines

National medicine policies

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Learning from low income countries: Poor patients deserve more science and less advocacy

Carol C Adelman and Jeremiah Norris
BMJ 2005 330: 479. [Extract] [Full Text]

Policies on essential drugs help contain costs
BMJ 2004 329: 0. [Full Text]

The pros and cons of essential medicines for rich countries

Marcus M Reidenberg and Tom Walley
BMJ 2004 329: 1172. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Patel, A., Gauld, R., Norris, P., Rades, T. (2009). "This body does not want free medicines": South African consumer perceptions of drug quality. Health Policy Plan 0: czp039v1-czp039 [Abstract] [Full text]  
• Adelman, C. C, Norris, J. (2005). Learning from low income countries: Poor patients deserve more science and less advocacy. BMJ 330: 479-479 [Full text]  
• Reidenberg, M. M, Walley, T. (2004). The pros and cons of essential medicines for rich countries. BMJ 329: 1172-1172 [Full text]  

Rapid Responses:

Read all Rapid Responses

Big Pharma vs Australian Pharmaceutical Benefits Scheme

Tom Hughes
bmj.com, 12 Nov 2004 [Full text]

Health and adequate education

Carlos Cuello
bmj.com, 12 Nov 2004 [Full text]

Poor Patients Deserve More Science and Less Advocacy

Carol C. Adelman, et al.
bmj.com, 25 Nov 2004 [Full text]

Patients need access to drugs not meddling from US conservative groups

Stuart Rennie
bmj.com, 3 Dec 2004 [Full text]

Online poll

Find out more here>> and here>>